Fresenius Kabi and Halyard Health Enter Distribution Agreement

By HospiMedica International staff writers
Posted on 04 Feb 2015
Fresenius Kabi (Bad Homburg, Germany), a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition, has signed a multi-year supply and distribution and agreement for Halyard Health (Alpharetta, GA, USA) disposable elastomeric intravenous (IV) infusion pumps.

The Halyard Health IV ambulatory infusion pumps include the Homepump Eclipse system, which is designed for antibiotic therapy, providing delivery times ranging from 30 minutes to 5 hours; the Homepump C-Series system is designed for continuous infusion, with delivery times ranging from 1 to 11 days, and is intended for chemotherapy and other protocols. Both systems provide medication through a catheter, but due to their light weight, compact size, and proven ease of use, they allow patients to receive the therapy in the comfort of their own homes.

Image: The Homepump Eclipse ambulatory infusion system (Photo courtesy of Halyard Health).

“This agreement demonstrates the company’s continued commitment to our philosophy of ‘caring for life’,” said Christian Hauer, president of the medical devices division of Fresenius Kabi. “By partnering with Halyard Health, we will be able to offer our customers an expanded range of products centered on key intravenously administered therapies, such as oncology and antibiotic treatment.”

The multi-year agreement with Halyard Health (formerly Kimberly-Clark Healthcare) covers several European markets, including Germany, Spain, Poland, Switzerland, and Austria. The United Kingdom and Ireland, which were already part of a multi-year distribution arrangement between Fresenius Kabi and Halyard Health, will also now come under the terms of this larger agreement.

Related Links:
Fresenius Kabi
Halyard Health


Latest Business News